Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Friday that the US Food and Drug Administration (FDA) has accepted its New Drug Application for investigational oral giredestrant plus everolimus to treat adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after prior endocrine therapy.
The agency set a Prescription Drug User Fee Act action date of 18 December 2026. The combined regimen could become the first oral selective oestrogen receptor degrader combination approved in the post-CDK4/6 inhibitor setting.
Acceptance of the filing is supported by Phase III evERA results showing the combination reduced risk of disease progression or death by 44% in the intention-to-treat (ITT) population and 62% in ESR1-mutated patients versus standard endocrine therapy plus everolimus.
Pfizer signs licensing agreement with Starna Therapeutics worth up to USD2.63bn
Ichnos Glenmark Innovation submits IND for ISB 2301 to treat solid tumours
Inhibrx updates clinical data for ozekibart (INBRX-109) in Ewing sarcoma
Onward Therapeutics closes Series B financing
Oncoinvent reports favourable interim safety results for Radspherin in phase 2 ovarian cancer trial
Apotex launches generic version of INLYTA in US market
Akeso submits sNDA for ivonescimab chemotherapy combination in first-line biliary tract cancer
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177
Guardant Health expands liquid biopsy test with AI-powered epigenomic applications